ArticleBioconjugate chemistry2026
Conjugates of Heme and Intrinsically Disordered Peptides toward the Development of Synthetic Artificial Oxygen Carriers.
Article in Bioconjugate chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial oxygen carriers (AOCs) remain an unmet medical need in clinical practice. While hemoglobin is relatively safe within red blood cells, its release into circulation causes complications due to hemoglobin degradation forming toxic hemin. Here we report the design and synthesis of a novel heme-intrinsically disordered peptide (Heme-IDP) conjugate as a potential prototype for next-generation AOCs. Heme-IDP demonstrates markedly reduced cytotoxicity compared with free hemin and protoporphyrin IX (PPIX). Fluorescence imaging further indicates that negatively charged IDP significantly reduces PPIX cellular uptake, contributing to improved biocompatibility of Heme-IDP. The use of d-enantiomeric IDP sequences enhances peptide stability. Spectroscopic analyses confirm that Heme-IDP retains the ability for axial binding. These results highlight the potential of d-peptide-based IDP to mitigate the intrinsic toxicity associated with heme derivatives, offering a promising new direction for the development of safer and more biocompatible AOCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.